When the vaccine is combined with immune checkpoint inhibitors (anti-CTLA4 and anti-PD-L1 antibodies) potent tumor specific immunity is induced in the neuroblastoma mouse model (20). This evidence concerns the gene CTLA4 and neuroblastoma.